MacroGenics Provides Update on Corporate Progress and First Quarter 2014 Financial Results

[GlobeNewswire] – Clinical study of first DART, MGD006, to commence in Second Quarter 2014 Phase 3 margetuximab gastroesophageal MAGENTA study poised for initiation in second half 2014 more

View todays social media effects on MGNX

View the latest stocks trending across Twitter. Click to view dashboard

See who MacroGenics is hiring next, click here to view